Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0002699,
umls-concept:C0007634,
umls-concept:C0012854,
umls-concept:C0012863,
umls-concept:C0013227,
umls-concept:C0023418,
umls-concept:C0036667,
umls-concept:C0086418,
umls-concept:C0205228,
umls-concept:C0312418,
umls-concept:C0441655,
umls-concept:C0521447,
umls-concept:C0733688,
umls-concept:C1704675
|
pubmed:issue |
2
|
pubmed:dateCreated |
1987-6-11
|
pubmed:abstractText |
The presumptive intracellular target of the anti-leukemia agents 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) is the enzyme topoisomerase II. We found that 350 mM NaCl extracts of nuclei from HL-60 and HL-60/AMSA, an m-AMSA resistant HL-60 subline, contained equivalent topoisomerase II activity. However, the ability of m-AMSA to stimulate cleavage of exogenous DNA and to stimulate crosslinking of exogenous DNA with protein, processes which are topoisomerase II-mediated, was greatly reduced in the HL-60/AMSA extracts compared to the HL-60 extracts. HL-60 and HL-60/AMSA were almost equally sensitive to the cytotoxic effects of VP-16 and differences in VP-16-stimulated, topoisomerase II-mediated exogenous DNA cleavage and protein crosslinking between HL-60 and HL-60/AMSA extracts were much less than the differences in m-AMSA-stimulated exogenous DNA cleavage and protein crosslinking. Thus, the interaction between topoisomerase II activity, exogenous DNA, and m-AMSA or VP-16 indicated the susceptibility HL-60 and HL-60/ AMSA to the cytotoxic effects of the drugs. A similar correlation may exist in explanted leukemia cells from patients with acute myelogenous leukemia.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0006-291X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
29
|
pubmed:volume |
144
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
787-93
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3034264-Amsacrine,
pubmed-meshheading:3034264-Animals,
pubmed-meshheading:3034264-Cell Line,
pubmed-meshheading:3034264-Cell Nucleus,
pubmed-meshheading:3034264-Crithidia,
pubmed-meshheading:3034264-DNA,
pubmed-meshheading:3034264-DNA Topoisomerases, Type II,
pubmed-meshheading:3034264-Humans,
pubmed-meshheading:3034264-Kinetics,
pubmed-meshheading:3034264-Leukemia, Myeloid, Acute,
pubmed-meshheading:3034264-Podophyllotoxin
|
pubmed:year |
1987
|
pubmed:articleTitle |
The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs.
|
pubmed:publicationType |
Journal Article
|